Literature DB >> 20813338

Identifying early prescribers of cycloxygenase-2 inhibitors (COX-2s) in Nova Scotia, Canada: Considerations for targeted academic detailing.

Kent E M Groves1, Tony Schellinck, Ingrid Sketris, Neil J MacKinnon.   

Abstract

BACKGROUND: Expenditures on prescribed drugs in Canada are now well past those for all services provided by outpatient physicians ($26.9 billion vs. $21.5 billion in 2007). Government has the opportunity to dedicate resources to continuing medical education of physicians, and effective profiling would assist in the allocation of these educational resources.
OBJECTIVE: The purpose of this study was to evaluate physician prescribing patterns and establish criteria by which various prescribing profiles may be segmented and identified, so as to better target detailing and continuing medical education resources.
METHODS: A sample of 925 physicians practicing in Nova Scotia (NS) was characterized by age, sex, rural/urban nature of their practice and specialty. They were subsequently evaluated relative to all prescriptions filled by their patients who were beneficiaries of the NS Department of Health's senior's Pharmacare drug insurance program. The adoption of COX-2 inhibitors (eg, Vioxx) and Celebrex) and their substitution for NS-NSAIDs (non-specific non-steroidal anti-inflammatory drugs, eg, Motrin) from 1999 to 2003 were examined.
RESULTS: This analysis established the profiles of 2 key groups of physicians. The first consisted of those most likely to comprise the early, high volume COX-2-prescribing universe (profiles based on the absolute number of prescriptions written over a given period). These individuals were likely to be older, more experienced, male general practitioners operating in a rural practice. The second group consisted of those most likely to comprise the early, high-relative, COX-2-prescribing universe (prescribing of COX-2s relative to non-selective, non-steroidal anti-inflammatory drugs (NS-NSAIDs)). These individuals were likely to be younger, less experienced female general practitioners, operating in an urban practice.
CONCLUSION: This research moves us closer to identifying unique physician segments that account for either the largest volume of prescriptions for new drugs, or the largest relative volume of prescriptions. Use of these physician groups can help continuing medical education providers target specific prescribers with information to assist them in examining and improving their prescribing. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20813338     DOI: 10.1016/j.sapharm.2009.09.003

Source DB:  PubMed          Journal:  Res Social Adm Pharm        ISSN: 1551-7411


  5 in total

1.  Regional Variance of the Early Use of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease.

Authors:  Reiko Inoue; Hiroshi Nishi; Daisuke Inoue; Kenjiro Honda; Masaomi Nangaku
Journal:  Kidney360       Date:  2020-06-16

Review 2.  Factors affecting the uptake of new medicines: a systematic literature review.

Authors:  Ágnes Lublóy
Journal:  BMC Health Serv Res       Date:  2014-10-20       Impact factor: 2.655

3.  Association between physician adoption of a new oral anti-diabetic medication and Medicare and Medicaid drug spending.

Authors:  Ilinca D Metes; Lingshu Xue; Chung-Chou H Chang; Haiden A Huskamp; Walid F Gellad; Wei-Hsuan Lo-Ciganic; Niteesh K Choudhry; Seth Richards-Shubik; Hasan Guclu; Julie M Donohue
Journal:  BMC Health Serv Res       Date:  2019-10-16       Impact factor: 2.655

4.  Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review.

Authors:  Kristina Medlinskiene; Justine Tomlinson; Iuri Marques; Sue Richardson; Katherine Stirling; Duncan Petty
Journal:  BMC Health Serv Res       Date:  2021-11-05       Impact factor: 2.655

5.  Evaluation of academic detailing programme on childhood diarrhoea management by primary healthcare providers in Banke district of Nepal.

Authors:  Saval Khanal; Mohamed Izham B Mohamed Ibrahim; Pathiyil Ravi Shankar; Subish Palaian; Pranaya Mishra
Journal:  J Health Popul Nutr       Date:  2013-06       Impact factor: 2.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.